Prognostic Values of Pregnancy-Associated Plasma Protein-A and IGF-Binding Protein-4 Fragments in Patients with Acute

Huan Li1, Zijian Wang2, Yichun Wang3

  • 1Department of Cardiology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Insights

Pregnancy-associated plasma protein-A (PAPP-A) and N-terminal IGF-binding protein-4 (NT-IGFBP-4) fragments predict adverse cardiovascular events in acute myocardial infarction (AMI) patients. NT-IGFBP-4 shows particular promise for AMI patients with early chronic kidney disease (CKD).

Area of Science:

  • Cardiology
  • Biomarkers
  • Renal Medicine

Background:

  • Vulnerable atherosclerotic plaques release Pregnancy-associated plasma protein-A (PAPP-A) and its derived N-terminal (NT-) and C-terminal (CT-) fragments of IGF-binding protein-4 (IGFBP-4).
  • These fragments are implicated in cardiovascular events.

Purpose of the Study:

  • To evaluate the prognostic value of PAPP-A, NT-IGFBP-4, and CT-IGFBP-4 in patients with acute myocardial infarction (AMI).
  • To assess the predictive significance of these biomarkers in AMI patients, particularly those with co-existing chronic kidney disease (CKD).

Main Methods:

  • Prospective study of 341 consecutive AMI patients, including 232 with early-stage CKD.
  • Measurement of admission serum levels of PAPP-A, NT-IGFBP-4, and CT-IGFBP-4.
  • Primary outcome: one-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE).

Main Results:

  • In the overall AMI cohort, elevated PAPP-A and NT-IGFBP-4 levels were significantly associated with MACCE.
  • In AMI patients with CKD, NT-IGFBP-4 independently predicted MACCE and cardiovascular death.
  • CT-IGFBP-4 levels did not differ significantly between patients with and without MACCE.

Conclusions:

  • PAPP-A and NT-IGFBP-4 are independent predictors of one-year MACCE in AMI patients.
  • NT-IGFBP-4 emerges as a potential prognostic biomarker for AMI patients, especially those with early-stage CKD.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...